Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
The life expectancy of people with type 1 diabetes has improved, but type 1 diabetes may accelerate aging and contribute to the development of frailty. Explore the underlying mechanisms, frailty assessment, and prevention strategies.
The novel oral GLP-1 receptor agonist orforglipron shows noninferior and potentially superior glycemic control versus oral semaglutide in type 2 diabetes, but with more gastrointestinal adverse events.
Metabolic and renal dysfunctions can influence the disease trajectory, treatment response, and prognosis of cardiomyopathies. A holistic and multidisciplinary approach is key to identifying the appropriate therapies.
SGLT2 inhibitors are linked to lower kidney, cardiovascular, and hepatic risks than DPP-4 inhibitors in patients with type 2 diabetes and liver cirrhosis.
Biotics have the potential to improve metabolic syndrome by reducing weight gain, insulin resistance, dyslipidemia, inflammation, and improving glycemic control and gut barrier function.
Insulin remains key to the management of type 2 diabetes, but its role continues to evolve with the arrival of once-weekly regimens presenting new opportunities and challenges. How can once-weekly insulin therapy be implemented to optimize patient care?
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
A 37-year-old woman developed acute encephalopathy and treatment-induced neuropathy of diabetes after 3 months of semaglutide use. Benefits of GLP-1 agonists outweigh the risks, but clinicians should be alert to potential sequelae.
A unusual case of bilateral lower-leg edema that developed in an older woman with SPIDDM shortly after she started basal–bolus insulin therapy with insulin aspart and insulin degludec.
What could be causing involuntary and uncontrolled movements in the right arm and leg of a woman with a 25-year history of diabetes and hypertension, beginning shortly after an intramuscular betamethasone injection for shoulder pain?
In this special edition of Medicine Matters, we're joined by Dr Gregory Lim, Claire Greenhill, and Sarah Onuora, Chief Editors of Nature Reviews Cardiology, Endocrinology, and Rheumatology, for a look back at the advances in their specialties in 2025.
Find out what caught their attention and why, and what they're looking forward to in 2026.
Background Melatonin has demonstrated anti-inflammatory, antioxidant, and immunomodulatory properties, making it a potential adjunct in periodontal therapy. However, its systemic metabolic effects, particularly on glycemic control in patients with …
The Research Society for the Study of Diabetes in India (RSSDI) Guidelines for the Management of Diabetes in Older Adults provide evidence-based, India-specific recommendations addressing the growing challenge of type 2 diabetes mellitus (T2DM) in …
Diabetes mellitus (DM) is a multifactorial disease driven by genetic and environmental factors, with type 2 diabetes mellitus (T2DM) constituting the majority of cases. A major cause of morbidity and mortality in diabetic patients is …
Intermittent fasting (IF) aids the management of obesity and impaired glucose homeostasis, although the comparative efficacy of different modes of IF on glycemic control remains unclear. The current review therefore aimed to investigate the …
In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.
Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.
Familiarize yourself with current and emerging ketone monitoring systems and the most useful clinical scenarios in which to use them through our podcasts and e-learning modules. Lower the barriers to effective prevention of diabetic ketoacidosis.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills with real cases, vodcasts, and interactive infographics.
The gastrointestinal tract plays a crucial role in maintaining metabolic and glucose homeostasis. Beyond its role in digestion and absorption, it regulates systemic metabolism and glucose levels through modulation of gut hormone secretion and the …
Metabolic bariatric surgery (MBS) is the most effective treatment option for achieving sustained weight loss in patients with obesity, while also improving obesity associated medical problems [ 1 , 2 ]. Among the various surgical options, Roux-en-Y …
Accurate interpretation of genetic variants in MODY genes is critical for diagnosis but remains a challenge in clinical practice. Variant classification remains challenging due to uncertainty regarding functional impact, the complexity of disease …
Autoimmune thyroid diseases (AITDs), primarily Graves’ disease (GD) and Hashimoto’s thyroiditis (HT), represent the most prevalent organ-specific autoimmune disorders (ADs) in Western countries [ 1 – 3 ]. The prevalence of HT-related hypothyroidism …
The life expectancy of people with type 1 diabetes has improved, but type 1 diabetes may accelerate aging and contribute to the development of frailty. Explore the underlying mechanisms, frailty assessment, and prevention strategies.
The novel oral GLP-1 receptor agonist orforglipron shows noninferior and potentially superior glycemic control versus oral semaglutide in type 2 diabetes, but with more gastrointestinal adverse events.
Given the association of MASLD with cardiovascular, renal, and endocrine metabolic disorders, should cardiovascular-kidney-metabolic syndrome evolve to metabolic-associated liver-cardiovascular-kidney syndrome?
The life expectancy of people with type 1 diabetes has improved, but type 1 diabetes may accelerate aging and contribute to the development of frailty. Explore the underlying mechanisms, frailty assessment, and prevention strategies.